肝动脉化疗性栓塞是目前肝癌非手术治疗最有效的方法，但其远期疗效差，并存在栓塞不全、缺乏靶向性、可控性差、毒副作用大等缺陷。为克服以上不足，本课题拟利用自主研发的肿瘤血管靶向性凝血蛋白，发展一种新型肝癌血管栓塞的治疗策略。用原位移植性肝癌模型，比较研究不同肿瘤血管靶向性凝血蛋白的血管栓塞活性、分子靶向特性、诱发凝血反应的分子机制及其主要影响因素，探讨靶向性凝血蛋白治疗肝癌的模式，阐明其治疗机理，为新型肝癌血管栓塞剂研制与应用提供理论基础与新思路。

Transcatheter arterial chemoembolization is the most effective method for the non operative treatment of liver cancer, but its long-term curative effect is poor, and there are defects such as incomplete embolization, lack of targeting, poor controllability, and large toxic and side effects. In order to overcome the above shortcomings, this study aims to develop a new therapeutic strategy for the liver cancer vascular embolization with the tumor vascular targeted blood coagulation proteins. we will observe the activity of vascular thrombosis and molecular targeting characteristics of the tumor vascular targeted blood coagulation proteins in orthotopic liver transplantation model, study the molecular mechanism of the their induced coagulation reactions and the main affecting factors, establish a new treatment model for the liver cancer vascular embolization, clarify the therapeutic mechanism, play theoretical basis and new ideas for the novel hepatocellular carcinoma vascular embolization agent development and application.